- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"
This study looks at new ways to treat early triple-negative breast cancer. It combines standard chemotherapy with a newer drug, Atezolizumab (or a dummy drug), to see if it can stop the cancer from coming back. It's a large study, comparing different treatment approaches.
For: Patients with early breast cancerGermany · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
This study compares two treatments for newly diagnosed Chronic Lymphocytic Leukemia (CLL). It looks at how well a combination of venetoclax and obinutuzumab works against standard treatments (FCR/BR) to reduce tiny amounts of cancer cells and improve overall health.
For: Chronic Lymphocytic Leukemia (CLL)Spain · France · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
This study looks at new drug combinations for children with specific types of cancer (Ewing sarcoma or neuroblastoma) that have come back or not responded to previous treatment. It tests how safe and effective these combinations are.
For: recurrent/refractory Ewing sarcoma · recurrent or refractory neuroblastomaSweden · France · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study
This study is looking at a new way to treat bladder cancer that has spread. It combines immunotherapy (pembrolizumab) with a cancer drug (cyclophosphamide) to see if it can stop the cancer from getting worse for longer. It's for adults and focuses on how well the treatment works.
For: metastatic urothelial cancerItaly